Current knowledge for pyridoxine-dependent epilepsy: a 2016 update

Expert Review of Endocrinology and Metabolism

Volumn 12, Issue 1, 2017, Pages 5-20

  Pena, Izabella Agostinho ^a,b   MacKenzie, Alex ^a,b   Van Karnebeek, Clara D M ^c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

aldh7a1; aminoadipate semialdehyde synthase; antiquitin; arginine supplementation; lysine restriction; pyridoxal phosphate; pyridoxine; Pyridoxine dependent epilepsy; recurrent seizures; treatment; vitamin B6

Indexed keywords

ANTICONVULSIVE AGENT; ARGININE; FOLINIC ACID; LYSINE; PIPERIDEINE 6 CARBOXYLATE; PYRIDINE DERIVATIVE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; BODY FLUID; DIET SUPPLEMENTATION; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; EPILEPSY; HUMAN; KNOWLEDGE; LONG TERM CARE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PYRIDOXINE DEPENDENT EPILEPSY; REVIEW;

EID: 85008467333     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1080/17446651.2017.1273107     Document Type: Review

References (145)

1. Gospe SM., Pyridoxine-Dependent Epilepsy. In:Pagon RA, Adam MP, Ardinger HH, et al., Editors. GeneReviews. Seattle (WA):University of Washington. 2014.
2. Hunt ADJ, Stokes JJ, McCRORY WW, et al. Pyridoxine dependency:report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954;13:140–145.
3. Baxter P. Pyridoxine-dependent and pyridoxine- responsive seizures. Dev Med Child Neurol. 2001;43:416–420. DOI:10.1111/j.1469-8749.2001.tb00231.x
4. Haenggeli CA, Girardin E, Paunier L. Pyridoxine-dependent seizures, clinical and therapeutic aspects. Eur J Pediatr. 1991;150:452–455.
5. Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child. 1999;81:431–433.
6. Van Karnebeek CDM, Tiebout SA, Niermeijer J, et al. Pyridoxine-dependent epilepsy:an expanding clinical spectrum. Pediatr Neurol. 2016;59:6–12. DOI:10.1016/j.pediatrneurol.2015.12.013• Recent review of published reports from 2006–2015 describing the most common symptoms and the broad clinical spectrum observed for 266 patient descriptions.
7. Gospe SMJ. Neonatal vitamin-responsive epileptic encephalopathies. Chang Gung Med J. 2010;33:1–12.
8. Ebinger M, Schultze C, Konig S. Demographics and diagnosis of pyridoxine-dependent seizures. J Pediatr. 1999;134:795–796.
9. Been JV, Bok LA, Andriessen P, et al. Epidemiology of pyridoxine dependent seizures in the Netherlands. Arch Dis Child. 2005;90:1293–1296. DOI:10.1136/adc.2005.075069
10. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12:307–309. DOI:10.1038/nm1366•• Article reporting the discovery of ALDH7A1 mutations as cause of PDE, leading of accumulation of AASA/P6C and inactivation of PLP.
11. Gallagher RC, Van Hove JLK, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65:550–556. DOI:10.1002/ana.21568
12. Struys EA, Bok LA, Emal D, et al. The measurement of urinary Δ1-piperideine-6-carboxylate, the alter ego of α-aminoadipic semialdehyde, in antiquitin deficiency. Inherit JMetab Dis. 2012;35:909–916.
13. Bok LA, Struys E, Willemsen MAAP, et al. Pyridoxine-dependent seizures in Dutch patients:diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis Child. 2007;92:687–689. DOI:10.1136/adc.2006.103192
14. Sadilkova K, Gospe SM, Hahn SH. Simultaneous determination of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acid-responsive seizures. J Neurosci Methods. 2009;184:136–141. DOI:10.1016/j.jneumeth.2009.07.019
15. Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. 2010;133:2148–2159. DOI:10.1093/brain/awq143• Detailed overview of genotypes and phenotypes observed in PDE patients suggesting a wide spectrum of symptoms and little genotypic-phenotypic correlation.
16. Stockler S, Plecko B, Gospe SM, et al. Pyridoxine dependent epilepsy and antiquitin deficiency. clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104:48–60. DOI:10.1016/j.ymgme.2011.05.014• Detailed and comprehensive review of PDE including clinical presentation, diagnosis, mutational spectrum, insights about pathophysiology and treatment options in 2011.
17. Topcu M, Coskun T, Haliloglu G, et al. Molybdenum cofactor deficiency:report of three cases presenting as hypoxic-ischemic encephalopathy. J Child Neurol. 2001;16:264–270.
18. Plecko B, Hikel C, Korenke G, et al. Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy. Neuropediatrics. 2005;36:200–205. DOI:10.1055/s-2005-865727
19. Mercimek-Mahmutoglu S, Donner EJ, Siriwardena K. Normal plasma pipecolic acid level in pyridoxine dependent epilepsy due to ALDH7A1 mutations. Mol Genet Metab. 2013;110:197. DOI:10.1016/j.ymgme.2013.04.018
20. Peduto A, Baumgartner MR, Verhoeven NM, et al. Hyperpipecolic acidaemia:a diagnostic tool for peroxisomal disorders. Mol Genet Metab. 2004;82:224–230. DOI:10.1016/j.ymgme.2004.04.010
21. Nasr E, Mamak E, Feigenbaum A, et al. Long-term treatment outcome of two patients with pyridoxine-dependent epilepsy caused by ALDH7A1 mutations:normal neurocognitive outcome. J Child Neurol. 2015;30:648–653. DOI:10.1177/0883073814531331
22. Jung S, Tran N-TB, Gospe SMJ, et al. Preliminary investigation of the use of newborn dried blood spots for screening pyridoxine-dependent epilepsy by LC-MS/MS. Mol Genet Metab. 2013;110:237–240. DOI:10.1016/j.ymgme.2013.07.017• First evidence for detection of AASA/P6C in newborn dried blood spots–towards newborn screening for PDE?
23. Pena IA, Marques LA, Laranjeira ABA, et al. Simultaneous detection of lysine metabolites by a single LC-MS/MS method:monitoring lysine degradation in mouse plasma. Springerplus. 2016;5:172. DOI:10.1186/s40064-016-1809-1
24. Yuzyuk T, Liu A, Thomas A, et al. A novel method for simultaneous quantification of alpha-aminoadipic semialdehyde/piperideine-6-carboxylate and pipecolic acid in plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1017–1018:145–152. DOI:10.1016/j.jchromb.2016.02.043
25. Mefford HC, Zemel M, Geraghty E, et al. Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by alu-alu recombination. Neurology. 2015;85:756–762. DOI:10.1212/WNL.0000000000001883
26. Kanno J, Kure S, Narisawa A, et al. Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab. 2007;91:384–389. DOI:10.1016/j.ymgme.2007.02.010
27. Pérez B, Gutiérrez-Solana LG, Verdú A, et al. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option. Epilepsia. 2013;54:239–248. DOI:10.1111/epi.12083
28. Bennett CL, Chen Y, Hahn S, et al. Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia. 2009;50:1167–1175. DOI:10.1111/j.1528-1167.2008.01816.x
29. Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat. 2007;28:19–26. DOI:10.1002/humu.20433
30. Salomons GS, Bok LA, Struys EA, et al. An intriguing “silent” mutation and a founder effect in antiquitin (ALDH7A1). Ann Neurol. 2007;62:414–418. DOI:10.1002/ana.21206
31. Scharer G, Brocker C, Vasiliou V. The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. J Inherit Metab Dis. 2010;33:571–581. DOI:10.1007/s10545-010-9187-2•• Description of the several genotypes and mutation types published for PDE until 2010. The authors studied the most common missense mutations and their possible implication in antiquitin function (based on structural and biochemical analysis). Suggestion of existence of three clinical phenotypes and three mutation classes for PDE patients but without clear association.
32. Brocker C, Lassen N, Estey T, et al. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. J Biol Chem. 2010;285:18452–18463. DOI:10.1074/jbc.M109.077925
33. Chan C-L, Wong JWY, Wong C-P, et al. Human antiquitin:structural and functional studies. Chem Biol Interact. 2011;191:165–170. DOI:10.1016/j.cbi.2010.12.019
34. Luo M, Tanner JJ. Structural basis of substrate recognition by aldehyde dehydrogenase 7A1. Biochemistry. 2015;54:5513–5522. DOI:10.1021/acs.biochem.5b00754
35. Coulter-Mackie MB, Li A, Lian Q, et al. Overexpression of human antiquitin in E. coli:enzymatic characterization of twelve ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. Mol Genet Metab. 2012;106:478–481. DOI:10.1016/j.ymgme.2012.06.008
36. Rankin PM, Harrison S, Chong WK, et al. Pyridoxine-dependent seizures:a family phenotype that leads to severe cognitive deficits, regardless of treatment regime. Dev Med Child Neurol. 2007;49:300–305. DOI:10.1111/j.1469-8749.2007.00300.x
37. Tlili A, Hamida Hentati N, Chaabane R, et al. Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of the ALDH7A1 gene. Gene. 2013;518:242–245. DOI:10.1016/j.gene.2013.01.041
38. Coulter-Mackie MB, Tiebout S, Van Karnebeek C, et al. Overexpression of recombinant human antiquitin in E. coli:partial enzyme activity in selected ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. Mol Genet Metab. 2014;111:462–466. DOI:10.1016/j.ymgme.2014.02.010
39. Bok LA, Been JV, Struys EA, et al. Antenatal treatment in two Dutch families with pyridoxine-dependent seizures. Eur J Pediatr. 2010;169:297–303. DOI:10.1007/s00431-009-1020-2
40. Al Teneiji A, Bruun TUJ, Cordeiro D, et al. Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy. Metab Brain Dis. 2016;1–9. DOI:10.1007/s11011-016-9933-8
41. Farrant RD, Walker V, Mills GA, et al. Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II. J Biol Chem. 2001;276:15107–15116. DOI:10.1074/jbc.M010860200
42. Takagi T, Bungo T, Tachibana T, et al. Intracerebroventricular administration of GABA-A and GABA-B receptor antagonists attenuate feeding and sleeping-like behavior induced by L-pipecolic acid in neonatal chicks. J Neurosci Res. 2003;73:270–275. DOI:10.1002/jnr.10656
43. Takagi T, Tachibana T, Saito E-S, et al. Central pipecolic acid increases food intake under ad libitum feeding conditions in the neonatal chick. Neurosci. Lett. 2003;347:93–96.
44. Takagi T, Ando R, Ohgushi A, et al. Intracerebroventricular injection of pipecolic acid inhibits food intake and induces sleeping-like behaviors in the neonatal chick. Neurosci Lett. 2001;310:97–100. DOI:10.1016/S0304-3940(01)02059-6
45. Gutiérrez MC, Delgado-Coello BA. Influence of pipecolic acid on the release and uptake of 3H.GABA from brain slices of mouse cerebral cortex. Neurochem Res. 1989;14:405–408. DOI:10.1007/BF00964852
46. Takahama K, Miyata T, Okano Y, et al. Potentiation of phenobarbital-induced anticonvulsant activity by pipecolic acid. Eur J Pharmacol. 1982;81:327–331.
47. Clayton PT. B6-responsive disorders:a model of vitamin dependency. J Inherit Metab Dis. 2006;29:317–326. DOI:10.1007/s10545-005-0243-2
48. Percudani R, Peracchi A. A genomic overview of pyridoxal-phosphate-dependent enzymes. EMBO Rep. 2003;4:850–854. DOI:10.1038/sj.embor.embor914
49. Gospe SMJ, Olin KL, Keen CL. Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet (London, England). 1994;343:1133–1134.
50. Kurlemann G, Ziegler R, Gruneberg M, et al. Disturbance of GABA metabolism in pyridoxine-dependent seizures. Neuropediatrics. 1992;23:257–259. DOI:10.1055/s-2008-1071353
51. Lott IT, Coulombe T, Di Paolo RV, et al. Vitamin B6-dependent seizures:pathology and chemical findings in brain. Neurology. 1978;28:47–54.
52. Goto T, Matsuo N, Takahashi T. CSF glutamate/GABA concentrations in pyridoxine-dependent seizures:etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control. Brain Dev. 2001;23:24–29.
53. Plecko B, Stockler S. Vitamin B6 dependent seizures. Can J Neurol Sci. 2009;36(Suppl 2):S73–7.
54. Mills PB, Surtees RAH, Champion MP, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5ʹ-phosphate oxidase. Hum Mol Genet. 2005;14:1077–1086. DOI:10.1093/hmg/ddi120
55. Mills P, Footitt E, Clayton PT. Vitamin B6 metabolism and inborn errors, in:online Metab. Mol Bases Inherit Dis. 2011. DOI:10.1036/ommbid.296
56. Scriver CR, Cullen AM. URINARY VITAMIN B6 AND 4-PYRIDOXIC ACID IN HEALTH AND IN VITAMIN B6 DEPENDENCY. Pediatrics. 1965;36:14–20.
57. Footitt EJ, Clayton PT, Mills K, et al. Measurement of plasma B6 vitamer profiles in children with inborn errors of vitamin B6 metabolism using an LC-MS/MS method. J Inherit Metab Dis. 2013;36:139–145. DOI:10.1007/s10545-012-9493-y
58. Kakee A, Takanaga H, Terasaki T, et al. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J Neurochem. 2001;79:110–118.
59. Yuzyuk T, Thomas A, Viau K, et al. Effect of dietary lysine restriction and arginine supplementation in two patients with pyridoxine-dependent epilepsy. Mol Genet Metab. 2016;118:167–172. DOI:10.1016/j.ymgme.2016.04.015
60. Struys EA, Jakobs C. Metabolism of lysine in alpha-aminoadipic semialdehyde dehydrogenase-deficient fibroblasts:evidence for an alternative pathway of pipecolic acid formation. FEBS Lett. 2010;584:181–186. DOI:10.1016/j.febslet.2009.11.055
61. Struys EA, Jansen EEW, Salomons GS. Human pyrroline-5-carboxylate reductase (PYCR1) acts on piperideine-6-carboxylate generating L-pipecolic acid. J Inherit Metab Dis. 2014;37:327–332. DOI:10.1007/s10545-013-9673-4
62. Brocker C, Cantore M, Failli P, et al. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chem Biol Interact. 2011;191:269–277. DOI:10.1016/j.cbi.2011.02.016
63. Basura GJ, Hagland SP, Wiltse AM, et al., Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures:review of 63 North American cases submitted to a patient registry., Eur J Pediatr. 168 (2009) 697–704. doi:10.1007/s00431-008-0823-x.•• Outline of the 63 cases submitted to the first PDE patient registry:natural history, diagnosis, treatment outcomes and management.
64. Baxter P, Griffiths P, Kelly T, et al. Pyridoxine-dependent seizures:demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol. 1996;38:998–1006.
65. Bejsovec M, Kulenda Z, Ponca E. Familial intrauterine convulsions in pyridoxine dependency. Arch Dis Child. 1967;42:201–207.
66. Baxter P, Aicardi J. Neonatal seizures after pyridoxine use. Lancet (London, England). 1999;354:2082–2083. DOI:10.1016/S0140-6736(05)76825-2
67. Coker SB. Postneonatal vitamin B6-dependent epilepsy. Pediatrics. 1992;90:221–223.
68. Bass NE, Wyllie E, Cohen B, et al. Pyridoxine-dependent epilepsy:the need for repeated pyridoxine trials and the risk of severe electrocerebral suppression with intravenous pyridoxine infusion. J Child Neurol. 1996;11:422–424.
69. Segal EB, Grinspan ZM, Mandel AM, et al. Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy. Pediatr Neurol. 2011;44:289–291. DOI:10.1016/j.pediatrneurol.2010.11.012
70. Kluger G, Blank R, Paul K, et al. Pyridoxine-dependent epilepsy:normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness. Neuropediatrics. 2008;39:276–279. DOI:10.1055/s-0029-1202833
71. Ohtsuka Y, Hattori J, Ishida T, et al. Long-term follow-up of an individual with vitamin B6-dependent seizures. Dev Med Child Neurol. 1999;41:203–206.
72. Poliachik SL, Friedman SD, Poliakov AV, et al. corpus callosum diffusion and connectivity features in high functioning subjects with pyridoxine-dependent epilepsy. Pediatr Neurol. 2016;54:43–48. DOI:10.1016/j.pediatrneurol.2015.09.012
73. Friedman SD, Ishak GE, Poliachik SL, et al. Callosal alterations in pyridoxine-dependent epilepsy. Dev Med Child Neurol. 2014;56:1106–1110. DOI:10.1111/dmcn.12511• First study report of postmortem brain from a proven PDE patient suggesting neuronal migration abnormalities and other structural brain defects.
74. Marguet F, Barakizou H, Tebani A, et al. Pyridoxine-dependent epilepsy:report on three families with neuropathology. Metab Brain Dis. 2016. DOI:10.1007/s11011-016-9869-z
75. Mercimek-Mahmutoglu S, Horvath GA, Coulter-Mackie M, et al. Profound neonatal hypoglycemia and lactic acidosis caused by pyridoxine-dependent epilepsy. Pediatrics. 2012;129:e1368–72. DOI:10.1542/peds.2011-0123
76. Jansen LA, Hevner RF, Roden WH, et al. Glial localization of antiquitin:implications for pyridoxine-dependent epilepsy. Ann Neurol. 2014;75:22–32. DOI:10.1002/ana.24027
77. Bok LA, Maurits NM, Willemsen MA, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia. 2010;51:2406–2411. DOI:10.1111/j.1528-1167.2010.02747.x
78. Naasan G, Yabroudi M, Rahi A, et al. Electroencephalographic changes in pyridoxine-dependant epilepsy:new observations. Epileptic Disord. 2009;11:293–300. DOI:10.1684/epd.2009.0280
79. Mikati MA, Trevathan E, Krishnamoorthy KS, et al. Pyridoxine-dependent epilepsy:EEG investigations and long-term follow-up., Electroencephalogr. Clin Neurophysiol. 1991;78:215–221.
80. Schmitt B, Baumgartner M, Mills PB, et al. Seizures and paroxysmal events:symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52:e133–42. DOI:10.1111/j.1469-8749.2010.03660.x
81. Nabbout R, Soufflet C, Plouin P, et al. Pyridoxine dependent epilepsy:a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed. 1999;81:F125–9.
82. Struys EA, Jakobs C. Alpha-aminoadipic semialdehyde is the biomarker for pyridoxine dependent epilepsy caused by alpha-aminoadipic semialdehyde dehydrogenase deficiency. Mol Genet Metab. 2007;91:405. DOI:10.1016/j.ymgme.2007.04.016
83. Struys EA, Nota B, Bakkali A, et al. Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency. Pediatrics. 2012;130:e1716–9. DOI:10.1542/peds.2012-1094
84. Mills PB, Footitt EJ, Ceyhan S, et al. Urinary AASA excretion is elevated in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. J Inheritmetab Dis. 2012;35:1031–1036. DOI:10.1007/s10545-012-9466-1
85. Plecko B, Paul K, Mills P, et al. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. 2014;82:1425–1433. DOI:10.1212/WNL.0000000000000344
86. Pearl PL, Hyland K, Chiles J, et al. Partial pyridoxine responsiveness in pnpo deficiency. JIMD Rep. 2013;9:139–142. DOI:10.1007/8904_2012_194• Study of 14 PDE cases in Netherlands describing long-term outcomes, suggesting poor outcome and correlations between patient characteristics and follow-up.
87. Mills PB, Camuzeaux SSM, Footitt EJ, et al. Epilepsy due to PNPO mutations:genotype, environment and treatment affect presentation and outcome. Brain. 2014;137:1350–1360. DOI:10.1093/brain/awu051
88. Darin N, Reid E, Prunetti L, et al. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-b6-dependent epilepsy. Am J Hum Genet. 2016;99:1325–1337. DOI:10.1016/j.ajhg.2016.10.011
89. Bok LA, Halbertsma FJ, Houterman S, et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol. 2012;54:849–854. DOI:10.1111/j.1469-8749.2012.04347.x
90. McLachlan RS, Brown WF. Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. Can J Neurol Sci. 1995;22:50–51.
91. Proudfoot M, Jardine P, Straukiene A, et al. Long-term follow-up of a successfully treated case of congenital pyridoxine-dependent epilepsy. JIMD Rep. 2013;10:103–106. DOI:10.1007/8904_2012_210
92. Baynes K, Farias ST, Gospe SMJ. Pyridoxine-dependent seizures and cognition in adulthood. Dev Med Child Neurol. 2003;45:782–785.
93. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr. 2004;9:98-101-109.
94. Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70. DOI:10.1016/j.yebeh.2014.05.031
95. Henshall DC, Meldrum BS. Cell death and survival mechanisms after single and repeated brief seizures. In:Noebels JL, Avoli M, Rogawski MA, et al., Editors. Jasper's Basic Mechanisms of the Epilepsies, 4th edition. Bethesda (MD):National Center for Biotechnology Information. 2012.
96. Van Karnebeek CDM, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol. 2015;17:335. DOI:10.1007/s11940-014-0335-0
97. Hartmann H, Fingerhut M, Jakobs C, et al. Status epilepticus in a neonate treated with pyridoxine because of a familial recurrence risk for antiquitin deficiency:pyridoxine toxicity?. Dev Med Child Neurol. 2011;53:1150–1153. DOI:10.1111/j.1469-8749.2011.04033.x
98. Wang H-S, Kuo M-F, Chou M-L, et al. Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child. 2005;90:512–515. DOI:10.1136/adc.2003.045963
99. Hoffmann GF, Schmitt B, Windfuhr M, et al. Pyridoxal 5ʹ-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis. 2007;30:96–99. DOI:10.1007/s10545-006-0508-4
100. Sudarsanam A, Singh H, Wilcken B, et al. cirrhosis associated with pyridoxal 5′-phosphate treatment of pyridoxamine 5′-phosphate oxidase deficiency. JIMD Rep. 2014;17:67–70. DOI:10.1007/8904_2014_338
101. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas:a randomized clinical trial. Jama. 2007;297:2351–2359. DOI:10.1001/jama.297.21.2351
102. Mak CM, Lee H-CH, Chan AY-W, et al. Inborn errors of metabolism and expanded newborn screening:review and update. Crit Rev Clin Lab Sci. 2013;50:142–162. DOI:10.3109/10408363.2013.847896
103. Kolker S, Garbade SF, Greenberg CR, et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-coa dehydrogenase deficiency. Pediatr Res. 2006;59:840–847. DOI:10.1203/01.pdr.0000219387.79887.86
104. Kolker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I–revised recommendations. J Inherit Metab Dis. 2011;34:677–694. DOI:10.1007/s10545-011-9289-5
105. Sniderman King L, Trahms C, Scott CR. Tyrosinemia type I. In:Pagon RA, Adam MP, Ardinger HH, et al., Editors. GeneReviews. Seattle (WA):University of Washington. 1993.
106. Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. DOI:10.1186/s13023-014-0130-8
107. Huang WJ, Zhang X, Chen WW. Gaucher disease:a lysosomal neurodegenerative disorder. Eur Rev Med Pharmacol Sci. 2015;19:1219–1226.
108. Stockler S, Moeslinger D, Herle M, et al. Cultural aspects in the management of inborn errors of metabolism. J Inherit Metab Dis. 2012;35:1147–1152. DOI:10.1007/s10545-012-9455-4
109. Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism:indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab. 2012;107:3–9. DOI:10.1016/j.ymgme.2012.07.005• First results of an open-label observational study of lysine restriction and first evidence for positive effects for the PDE patients.
110. Van Vliet D, Derks TGJ, Van Rijn M, et al. Single amino acid supplementation in aminoacidopathies:a systematic review. Orphanet J Rare Dis. 2014;9:7. DOI:10.1186/1750-1172-9-7
111. Muller E, Kolker S. Reduction of lysine intake while avoiding malnutrition–major goals and major problems in dietary treatment of glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27:903–910. DOI:10.1023/B:BOLI.0000045775.03183.48•• Detailed recommendations for lysine-restricted therapy:management, monitoring and follow-up strategies based on the PDE Consortium consensus.
112. Van Karnebeek CDM, Hartmann H, Jaggumantri S, et al. Lysine restricted diet for pyridoxine-dependent epilepsy:first evidence and future trials. Mol Genet Metab. 2012;107:335–344. DOI:10.1016/j.ymgme.2012.09.006• First suggestion of the use of arginine supplementation as adjunct to pyridoxine for PDE with the description of one case study.
113. Mercimek-Mahmutoglu S, Corderio D, Nagy L, et al. Lysine-restricted diet and mild cerebral serotonin deficiency in a patient with pyridoxine-dependent epilepsy caused by ALDH7A1 genetic defect. Mol Genet Metab Reports. 2014;1:124–128. DOI:10.1016/j.ymgmr.2014.02.001
114. Van Karnebeek CDM, Stockler-Ipsiroglu S, Jaggumantri S, et al. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy:the pde consortium consensus recommendations. JIMD Rep. 2014;15:1–11. DOI:10.1007/8904_2014_296
115. Mercimek-Mahmutoglu S, Cordeiro D, Cruz V, et al. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect:l-arginine supplementation alternative to lysine-restricted diet. Eur J Paediatr Neurol. 2014;18:741–746. DOI:10.1016/j.ejpn.2014.07.001• First description of triple therapy (lysine-restricted diet, arginine supplementation and pyridoxine treatment) describing management, follow-ups and outcomes in six patients.
116. O’Kane RL, Vina JR, Simpson I, et al. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab. 2006;291:E412–9. DOI:10.1152/ajpendo.00007.2006
117. Stoll J, Wadhwani KC, Smith QR. Identification of the cationic amino acid transporter (system y+) of the rat blood-brain barrier. J Neurochem. 1993;60:1956–1959.
118. 2nd Coughlin CR, Van Karnebeek CDM, Al-Hertani W, et al. Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy:neurodevelopmental outcome. Mol Genet Metab. 2015;116:35–43. DOI:10.1016/j.ymgme.2015.05.011
119. Mahajnah M, Corderio D, Austin V, et al. A prospective case study of the safety and efficacy of lysine-restricted diet and arginine supplementation therapy in a patient with pyridoxine-dependent epilepsy caused by mutations in ALDH7A1. Pediatr Neurol. 2016;60:60–65. DOI:10.1016/j.pediatrneurol.2016.03.008
120. Ho G, Ueda K, Houben RFA, et al. Metabolic Diet App Suite for inborn errors of amino acid metabolism. Mol Genet Metab. 2016;117:322–327. DOI:10.1016/j.ymgme.2015.12.007
121. Dwyer TM, Rao KS, Goodman SI, et al. proton abstraction reaction, steady-state kinetics, and oxidation−reduction potential of human glutaryl-coa dehydrogenase. Biochemistry. 2000;39:11488–11499. DOI:10.1021/bi000700g
122. Sauer SW, Okun JG, Fricker G, et al. Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-coA dehydrogenase deficiency. J Neurochem. 2006;97:899–910. DOI:10.1111/j.1471-4159.2006.03813.x
123. Kolker S, Boy SPN, Heringer J, et al. Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type I - A decade of experience. Mol Genet Metab. 2012;107:72–80. DOI:10.1016/j.ymgme.2012.03.021
124. Strauss KA, Puffenberger EG, Robinson DL, et al. Type I glutaric aciduria, part 1:natural history of 77 patients. Am J Med Genet C Semin Med Genet. 2003;121C:38–52. DOI:10.1002/ajmg.c.20007
125. Heringer J, Boy SPN, Ensenauer R, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol. 2010;68:743–752. DOI:10.1002/ana.22095
126. Strauss KA, Brumbaugh J, Duffy A, et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-coA dehydrogenase deficiency:focus on cerebral amino acid influx. Mol Genet Metab. 2011;104:93–106. DOI:10.1016/j.ymgme.2011.07.003
127. Sauer SW, Opp S, Hoffmann GF, et al. Therapeutic modulation of cerebral l-lysine metabolism in a mouse model for glutaric aciduria type I. Brain. 2011;134:157–170. DOI:10.1093/brain/awq269
128. Yannicelli S. Nutrition management of patients with inherited disorders of organic acid metabolism. In:Acosta P, Editor. Nutrition management of patients with inherited metabolic disorders. Boston:Jones and Bartlett publishers; 2010. p. 314.
129. Zinnanti WJ, Lazovic J, Wolpert EB, et al. A diet-induced mouse model for glutaric aciduria type I. Brain. 2006;129:899–910. DOI:10.1093/brain/awl009
130. Viau K, Ernst SL, Vanzo RJ, et al. Glutaric acidemia type 1:outcomes before and after expanded newborn screening. Mol Genet Metab. 2012;106:430–438. DOI:10.1016/j.ymgme.2012.05.024
131. Higashino Y, Fujioka K, Yamamura M. The conversion of l-lysine to saccharopine and α-aminoadipate in mouse.Arch Biochem Biophys. 1971;142:606–614. DOI:10.1016/0003-9861(71)90525-X
132. Blemings N, Crenshaw KP, Swick TD, et al. Lysine-α-ketoglutarate reductase and saccharopine dehydrogenase are located only in the mitochondrial matrix in rat liver. J Nutr. [Internet]. 1994;124:1215–1221.
133. Papes F, Kemper EL, Cord-Neto G, et al. involvement of both bifunctional and monofunctional lysine-degrading enzymes in mouse. Biochem J. 1999;344:555–563.
134. Papes F, Surpili MJ, Langone F, et al. The essential amino acid lysine acts as precursor of glutamate in the mammalian central nervous system. FEBS Lett. [Internet]. 2001;488:34–38.
135. Pena IA, Marques LA, Laranjeira ABA, et al. Mouse lysine catabolism to aminoadipate occurs primarily through the saccharopine pathway; implications for pyridoxine dependent epilepsy (PDE). Biochim Biophys Acta. 2017;1863:121–128. DOI:10.1016/j.bbadis.2016.09.006
136. Rzem R, Achouri Y, Marbaix E, et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. Plos One. 2015;10. DOI:10.1371/journal.pone.0119540
137. Posset R, Opp S, A Struys E, et al. Understanding cerebral L-lysine metabolism:the role of L-pipecolate metabolism in gcdh-deficient mice as a model for glutaric aciduria type I. J Inherit Metab Dis. 2014. DOI:10.1007/s10545-014-9762-z
138. Markovitz PJ, Chuang DT, Cox RP. Familial hyperlysinemias. Purification and characterization of the bifunctional aminoadipic semialdehyde synthase with lysine-ketoglutarate reductase and saccharopine dehydrogenase activities. J Biol Chem. 1984;259:11643–11646.
139. Houten SM, Te Brinke H, Denis S, et al. Genetic basis of hyperlysinemia. Orphanet J Rare Dis. [Internet]. 2013;8:57. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3626681&tool=pmcentrez&rendertype=abstract
140. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis. 2001;21:563–571. DOI:10.1055/s-2001-19035
141. Coutinho MF, Santos JI, Alves S. Less is more:substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17. DOI:10.3390/ijms17071065
142. Butters TD, Mellor HR, Narita K, et al. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci. 2003;358:927–945. DOI:10.1098/rstb.2003.1278
143. Platt FM, Jeyakumar M, Andersson U, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis. 2001;24:275–290.
144. Mihalik SJ, Rhead WJ. Species variation in organellar location and activity o f L-pipecolic acid oxidation in mammals. J Comp Physiol B. 1991;160:671–675.
145. Broquist HP. L ysine-pipecolic acid metabolic relationships in microbes and mammals. Annu Rev Nutr. 1991;11:435–438.